Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 24;13:856657. doi: 10.3389/fimmu.2022.856657

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Busà, Sorrentino, Russelli, Amico, Miceli, Miele, Di Bella, Timoneri, Gallo, Zito, Di Carlo, Conaldi and Bulati

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Kinetic of total anti-SARS-CoV-2 IgG and IgA serum antibodies levels in seronegative recipients (ICs n=11) of Pfizer-BioNTech BNT162b2 mRNA-based vaccination. The evaluation of both serum antibodies was conducted at three weeks (T1) and nine months (T2) after the second dose, and three weeks after the booster dose (T3). In Figure (A) anti-SARS-CoV-2 S1/S2 IgG levels and in (B) anti-SARS-CoV-2 S1 IgA levels. The dotted lines correspond to IgG (> 15.0 AU/mL) and IgA (>1.1 Ratio) cut-off, respectively. The significance was determined using Tukey’s multiple comparisons test. One-way ANOVA, ***p=0.0002; ****p<0.0001, ns, not significant.